[Effect of enterosorption on immunologic parameters of patients with colorectal cancer in the postoperative period].
Our investigation was carried out on an assumption that end results among patients radically-treated for colorectal cancer might be improved by use of enteroabsorption. The study group included 17, controls--13 patients with diagnostically verified stage I-III tumors. Mixed sorbent (microcellulose + polysorb) (6g) was administered, once a week, on the average of 20 days after operation. Immunological vigor was assayed 3 weeks after surgery: immunoglobulin levels--by turbodimetric method, cellular profile of lymphocytes--monoclonal antibodies to cell markers CD3, CD4, CD8, CD16 and CD22. As a result of adjuvant treatment CD22 (B-lymphocytes) concentration increased significantly--from 17.70 to 21.66 (22%), while CD16 (innate killers) both in absolute numbers (19%) and by percentage points (9%). Circulating immunocomplex levels in the sorbent-treatment group were significantly lower (37.44 ths units) than in control (48 ths units) (average 28%). No relapse or metastases were reported in either group.
G M
GM
Manikhas
V A
VA
Akhytin
M Kh
MKh
Fridman
A V
AV
Solomennikov
M S
MS
Palkanova
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects; D017252:CD3 Complex / Q000187:drug effects; D015704:CD4 Antigens / Q000187:drug effects; D016827:CD8 Antigens / Q000187:drug effects; D002482:Cellulose / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D003176:Complement C3 / Q000187:drug effects; D003181:Complement C4 / Q000187:drug effects; D016061:Enterosorption; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000187:drug effects; D007694:Killer Cells, Natural / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011108:Polymers / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D017452:Receptors, IgG / Q000187:drug effects; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000187:drug effects
D015703:Antigens, CD; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D003176:Complement C3; D003181:Complement C4; D007136:Immunoglobulins; D011108:Polymers; D017452:Receptors, IgG; D051918:Sialic Acid Binding Ig-like Lectin 2; C048851:polysorb; D002482:Cellulose